Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibutamoren. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.98 |
| ▸ | TACR1 | P25103 | 19/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibutamoren SCHEMBL4451194 | 1.00 | GHSR (0.98) | GHSRTACR1 | |
| Ibutamoren SCHEMBL29366896 | 1.00 | GHSR (0.98) | GHSRTACR1 | |
| Ibutamoren SCHEMBL29369919 | 0.99 | GHSR (1.00) | GHSRTACR1 | |
| Ibutamoren SCHEMBL739398 | 0.99 | GHSR (1.00) | GHSRTACR1 | |
| Ibutamoren SCHEMBL4927761 | 0.99 | GHSR (1.00) | GHSRTACR1 | |
| Ibutamoren SCHEMBL7413830 | 0.98 | GHSR (0.98) | GHSRTACR1 | |
| Ibutamoren SCHEMBL7413834 | 0.98 | GHSR (0.98) | GHSRTACR1 | |
| SCHEMBL12798402 | 0.93 | GHSR (0.88) | GHSRTACR1 | |
| SCHEMBL6802758 | 0.92 | GHSR (0.84) | GHSRTACR1 | |
| SCHEMBL7570569 | 0.92 | GHSR (0.87) | GHSRTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001475-B1 | METHODS FOR TREATING SARCOPENIA WITH A GROWTH HORMONE SECRETAGOGUE | THORNER MICHAEL O (US) | 2018-11-14 | — | — | EP | claimed |
| EP-2001475-A2 | METHODS FOR TREATING SARCOPENIA WITH A GROWTH HORMONE SECRETAGOGUE | Thorner, Michael O. (US) | 2008-12-17 | — | — | EP | claimed |
| US-7442706-B2 | Methods for treating sarcopenia with a growth hormone secretagogue | AMMONETT PHARMA, LLC | 2008-10-28 | — | — | US | claimed |
| WO-2007106792-A2 | METHODS FOR TREATING SARCOPENIA WITH A GROWTH HORMONE SECRETAGOGUE | THORNER MICHAEL O (US) | 2007-09-20 | — | — | WO | claimed |
| US-20070219226-A1 | METHODS FOR TREATING SARCOPENIA WITH A GROWTH HORMONE SECRETAGOGUE | AMMONETT PHARMA, LLC | 2007-09-20 | — | — | US | claimed |
| US-20040063641-A1 | Use of growth hormone or a growth hormone secretagogue for promoting bone formation | RASCHKE MICHAEL (DE) | 2004-04-01 | — | — | US | claimed |
| EP-1156808-A2 | ENHANCEMENT OF RETURN TO INDEPENDENT LIVING STATUS WITH A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 2001-11-28 | — | — | EP | claimed |
| US-6194402-B1 | ADMINISTERING A COMPOUND TO STIMULATE THE EFFECTS OF SOMATOTROPINS TO PATIENTS AFTER ACUTE DECONDITIONING SUCH AS THAT WHICH MAY RESULT FROM IMMOBILIZATION, SURGERY, OR MAJOR INJURY, E.G., HIP FRACTURE; | MERCK & CO., INC. | 2001-02-27 | — | — | US | claimed |
| US-6123964-A | N-(1(R)-((1,2-DIHYDRO-1-METHANESULFONYLSPIRO(3H-INDOLE-3,4' -PIPERDIN)-1'-YL)CARBONYL)-2-(PHENYLMETHYLOXY)ETHYL)-2-AMINO-2-METHYL -PROPANAMIDE, SPECIFIED BINDER/DILUENT, FIRST AND SECOND DILUENTS, DISINTEGRANT, AND LUBRICANT(S); TABLETS | MERCK & CO., INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-1019402-A1 | POLYMORPHIC FORMS OF A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| EP-0857020-A4 | WET GRANULATION FORMULATION OF A GROWTH HORMONE SECRETAGOGUE | MERCK & CO INC (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1998046220-A1 | COMBINATION THERAPY FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | MERCK & CO., INC. (US) | 1998-10-22 | — | — | WO | claimed |
| EP-0857020-A1 | WET GRANULATION FORMULATION OF A GROWTH HORMONE SECRETAGOGUE | Merck & Co., Inc. (US) | 1998-08-12 | — | — | EP | claimed |
| WO-1998025622-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING BONE LOSS | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | claimed |
| WO-1998025463-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING BONE LOSS | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | claimed |
| EP-0813414-A1 | COMBINATION OF BISPHOSPHONATES AND GROWTH HORMONE SECRETAGOGUES | MERCK & CO. INC. (US) | 1997-12-29 | — | — | EP | claimed |
| WO-1997015191-A1 | WET GRANULATION FORMULATION OF A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| WO-1997015574-A1 | POLYMORPHIC FORMS OF A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| US-5536716-A | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO., INC. (US) | 1996-07-16 | — | — | US | claimed |
| WO-1995011029-A1 | COMBINATION OF BISPHOSPHONATES AND GROWTH HORMONE SECRETAGOGUES | MERCK & CO., INC. (US) | 1995-04-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063641-A1 | Use of growth hormone or a growth hormone secretagogue for promoting bone formation | GHSR, GHRHR, BMP2 | GHSR 1/4885TACR1 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.